An Educational Webinar
Reducing Recurrent Stroke Risk with CYP2C19 Genotype-Guided DAPT
Learning Objectives:
- Understand the Role of Pharmacogenetics in Patient Response to Clopidogrel and its Impact in Dual Antiplatelet Therapy
Learn how CYP2C19 genotypes influence the efficacy and safety of dual antiplatelet therapy in stroke management and interventional neurology.
- Evaluate Clinical Evidence Supporting CYP2C19 Genotype-Guided Dual Antiplatelet Therapy
Review key clinical trial data and guidelines demonstrating the impact of tailoring antiplatelet therapy based on CYP2C19 genotype.
- Understand the Process of Implementing Rapid CYP2C19 Testing into Clinical Practice
Explore practical strategies for integrating rapid CYP2C19 genotyping into stroke care and interventional neurology workflows.
Robert W. Regenhardt, MD, PhD
Vascular and Interventional Neurologist
UTHealth Houston
1 HOUR CYP2C19 GENOTYPING
FDA 510(k)-Cleared and CE Marked
Rapid CYP2C19 Genotyping can aid in the implementation of genotype-guided dual antiplatelet therapy (DAPT)1
Rapid CYP2C19 Genotyping can aid in the implementation of genotype-guided dual antiplatelet therapy (DAPT)1
U.S. AHA/ASA guidelines2 recommend dual antiplatelet therapy (DAPT) within 12-24 hours of first stroke or TIA to prevent recurrent stroke for minor stroke or high-risk TIA. Clinical Pharmacogenetic Implementation Consortium (CPIC) guidelines recommend ticagrelor in place of clopidogrel in minor stroke/high-risk TIA patients carrying a CYP2C19 loss of function allele1. The June 2024 AHA Scientific Statement recommends CYP2C19 genetic testing for ACS and PCI patients to decrease the risk of ischemic events while reducing bleeding risks associated with ticagrelor and prasugrel treatments.3
The Genomadix Cube System Tests for...
- Lee et al., Clin Pharmacol Ther. 2022 November ; 112(5): 959–967. doi:10.1002/cpt.2526 |
- Kleindorfer DO, et al. Stroke. 2021;52:e364–e467.
- Pereira et al. Circulation. 2024;150:e129-e150. DOI: 10.1161/CIR.0000000000001257.
